PMID- 17273744
OWN - NLM
STAT- MEDLINE
DCOM- 20070502
LR  - 20211203
IS  - 1021-335X (Print)
IS  - 1021-335X (Linking)
VI  - 17
IP  - 3
DP  - 2007 Mar
TI  - Kinesin superfamily protein-derived peptides with the ability to induce 
      glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A24+ glioma 
      patients.
PG  - 629-36
AB  - One promising modality in the treatment of malignant glioma is specific 
      immunotherapy. However, this modality requires information about target antigens 
      and their epitope peptides that are recognized by T cells. In this study, we 
      searched for new target candidates in specific immunotherapy for malignant glioma 
      by utilizing cDNA microarray technology to compare gene expressions in malignant 
      glioma tissues to those in benign glioma and a panel of normal tissues. The 
      selected genes included three members of the kinesin superfamily proteins (KIFs): 
      KIF1C, KIF3C, and KIF21B. RT-PCR showed that these three genes were expressed in 
      the majority of glioma cell lines. These antigen-derived 25 peptides, which had 
      the ability to bind to human leukocyte antigen (HLA)-A24 molecules, were first 
      screened for their ability to be recognized by the immunoglobulin G of glioma 
      patients, and then tested for their potential to induce peptide-specific and 
      glioma-reactive cytotoxic T lymphocytes (CTLs) from the peripheral blood 
      mononuclear cells of HLA-A24+ glioma patients. The results showed that the 
      KIF1C149-158 and KIF3C512-520 peptides efficiently induced HLA-A24-restricted and 
      glioma-reactive CD8+ T cells. These results suggest the existence of KIF-reactive 
      CTL precursors in glioma patients, and should facilitate the development of 
      specific immunotherapies for malignant glioma.
FAU - Harada, Mamoru
AU  - Harada M
AD  - Department of Immunology, Kurume University Research Center for Innovative Cancer 
      Therapy, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
FAU - Ishihara, Yuki
AU  - Ishihara Y
FAU - Itoh, Kyogo
AU  - Itoh K
FAU - Yamanaka, Ryuya
AU  - Yamanaka R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-A24 Antigen)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Peptides)
RN  - 0 (RNA, Messenger)
RN  - EC 3.6.4.4 (Kinesins)
SB  - IM
MH  - Antigens, Neoplasm/immunology/*isolation & purification
MH  - Brain Neoplasms/*immunology/therapy
MH  - Cancer Vaccines
MH  - Cell Line, Tumor
MH  - Gene Expression
MH  - Gene Expression Profiling
MH  - Glioma/*immunology/therapy
MH  - HLA-A Antigens/*immunology
MH  - HLA-A24 Antigen
MH  - Humans
MH  - Immunoglobulin G/blood/immunology
MH  - Immunotherapy/methods
MH  - Kinesins/*immunology
MH  - Oligonucleotide Array Sequence Analysis
MH  - Peptides/immunology
MH  - RNA, Messenger/analysis
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - T-Lymphocytes, Cytotoxic/*immunology
EDAT- 2007/02/03 09:00
MHDA- 2007/05/03 09:00
CRDT- 2007/02/03 09:00
PHST- 2007/02/03 09:00 [pubmed]
PHST- 2007/05/03 09:00 [medline]
PHST- 2007/02/03 09:00 [entrez]
PST - ppublish
SO  - Oncol Rep. 2007 Mar;17(3):629-36.